Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial

BACKGROUND: Several studies have suggested that proton pump inhibitors (PPIs) may reduce the antiplatelet effects of clopidogrel and/or aspirin, possibly leading to cardiovascular events. AIMS: We aimed to investigate the association between PPI and clinical outcomes in patients treated with ticagre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ono, Masafumi, Onuma, Yoshinobu, Kawashima, Hideyuki, Hara, Hironori, Gao, Chao, Wang, Rutao, O'Leary, Neil, Benit, Edouard, Janssens, Luc, Ferrario, Maurizio, Żurakowski, Aleksander, Dominici, Marcello, Huber, Kurt, Buszman, Paweł, Garg, Scot, Wykrzykowska, Joanna J., Piek, Jan J., Jüni, Peter, Hamm, Christian, Windecker, Stephan, Vranckx, Pascal, Deliargyris, Efthymios N., Bhatt, Deepak L., Storey, Robert F., Valgimigli, Marco, Serruys, Patrick W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Coronary Artery Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541955/
https://www.ncbi.nlm.nih.gov/pubmed/35500171
http://dx.doi.org/10.1002/ccd.30217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541955/
https://www.ncbi.nlm.nih.gov/pubmed/35500171
http://dx.doi.org/10.1002/ccd.30217

Ejemplares similares